To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected]
Berlin, Germany, November 3, 2021, 08:00 CET – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), today announces that Due to supply problems affecting the company in charge of the production of its drugs, the start of its next two clinical trials evaluating NOX-A12 will be delayed by a maximum of 3 months, until the third quarter of 2022. The trials concerned are phase 2 trial (OPTIMUS) evaluating NOX-A12 in combination with anti-PD-1 treatment Keytruda® (pembrolizumab) from MSD (Merck & Co., Inc., Kenilworth, NJ USA) in the treatment of second-line pancreatic cancer; and the pivotal phase 2/3 trial that will evaluate NOX-A12 in combination with radiotherapy as a first-line treatment in patients with brain cancer (glioblastoma).
– .
